The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04.
 
Shanu Modi
Honoraria - Daiichi Sankyo/Astra Zeneca; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lilly; Macrogenics; Puma Biotechnology; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Naoki Niikura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Nihon Medi-Physics; Nippon Kayaku; Pfizer; Puma Biotechnology; Taiho Pharmaceutical; Takeda
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Nihonkayaku (Inst); Taiho Pharmaceutical (Inst)
 
William Jacot
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Lilly O.; MSD; Novartis; Pfizer; Roche; Seagan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Lilly O.; MSD; Novartis; Pfizer; Roche; Seagan
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Chugai Pharma; Eisai; GlaxoSmithKline; Lilly O.; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi/Aventis
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagan (Inst)
 
Eriko Tokunaga
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly Japan
 
Maria Jesus Vidal
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Novartis/Pfizer; Pfizer; Roche
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Novartis/Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Gilead Sciences; Pfizer
 
Yeon Hee Park
Honoraria - AstraZeneca; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Genome Insight (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
 
Keun Seok Lee
Consulting or Advisory Role - Bixink; Everest Pharmaceutical; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Dong-A ST
 
Yeesoo Chae
No Relationships to Disclose
 
Naoto T. Ueno
Stock and Other Ownership Interests - Pear Bio
Honoraria - Amgen; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Henry Stewart Talks; Kyowa Hakko Kirin; Kyowa Kirin International; Novartis; Pfizer; Pfizer; Puma Biotechnology; Rakuten Medical; Sumitomo Dainippon Pharma Oncology; Sysmex; Taiho Pharmaceutical
Consulting or Advisory Role - Carna Biosciences; Daiichi Sankyo; Eisai; Immunomedics; Kechow Pharma; OncoCyte; Phoenix Molecular Designs; Preferred Medicine; Takeda
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; CytoDyn; Daiichi Sankyo; Duality Biologics; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Preferred Medicine; Puma Biotechnology; Sysmex
 
Aleix Prat
Employment - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Fumitaka Suto
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Yusuke Kuwahara
Employment - Daiichi Sankyo Pharmaceutical
Stock and Other Ownership Interests - Daiichi Sankyo Pharmaceutical
 
Robert McEwen
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Wenqin Feng
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo; Merck
 
Hiroki Goto
Employment - Daiichi Sankyo RD Novare
 
Cecilia Orbegoso
Employment - AstraZeneca; Daiichi Sankyo; Pierre Fabre
Stock and Other Ownership Interests - Daiichi Sankyo
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
 
Junji Tsurutani
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Nihonkayaku; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Daiichi Sankyo; Lilly; Seagen
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Kirin (Inst); Lilly (Inst); MSD Oncology (Inst); Nihonkayaku (Inst); Pfizer (Inst); Sant Joan de Déu Research Foundation (FSJD) (Inst); West Japan Oncology Group (Inst); West Japan Oncology Group (Inst)